Europe Nucleic Acid Isolation and Purification Market
Europe Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, mRNA), Application (Diagnostics, Personalized Medicine), End User (CROs) - Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Europe nucleic acid isolation and purification market is projected to reach USD 2.41 billion by 2030 from USD 1.61 billion in 2025, at a CAGR of 8.4% from 2025 to 2030. The growth of the Europe nucleic acid isolation and purification market is strongly linked to the region’s high volume of molecular tests and the steady adoption of PCR- and NGS-based workflows. Hospitals, public health labs, and reference laboratories need clean, inhibitor-free DNA/RNA for routine diagnostics, oncology panels, and sequencing. Demand is also rising in infectious disease surveillance, genetic screening, and liquid biopsy/cfDNA testing, where extraction quality directly impacts sensitivity.
KEY TAKEAWAYS
-
By CountryGermany accounted for a 33.9% revenue share of the Europe nucleic acid isolation and purification market in 2024.
-
By ProductBy product, the kits segment is projected to register the highest growth rate of 8.8% in the Europe nucleic acid isolation and purification market during the forecast period.
-
By TypeBy type, the plasmid DNA isolation and purification segment is projected to register a CAGR of 10.0% during the forecast period.
-
By methodBy method, the magnetic bead-based isolation and purification segment dominated the market in 2024.
-
By ApplicationBy application, the personalized medicine segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive Landscape - Key PlayersCompanies such as Thermo Fisher Scientific, Merck KGaA, and QIAGEN were identified as some of the key players in the Europe nucleic acid isolation and purification market, given their strong market share and product footprint.
-
Competitive Landscape - Startups/SMEsCompanies such as PCR Biosystems and LGC Biosearch Technologies, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The Europe nucleic acid isolation and purification market is growing with the steady rise in PCR- and NGS-based testing across both clinical and research laboratories. There is an increasing need for high-purity, consistent DNA/RNA to support oncology panels, infectious disease testing, genetic screening, and microbiome research. In Europe, liquid biopsy and cfDNA workflows are also growing and these sample types demand stringent extraction performance to protect sensitivity and reduce variability.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders’ businesses in the Europe nucleic acid isolation and purification market is shaped by the region’s shift toward molecular decision-making in healthcare and life sciences. As PCR, qPCR, and NGS become routine across infectious disease testing, oncology profiling, and genetic screening, the demand is rising for high-quality, inhibitor-free DNA/RNA extraction as a critical first step. Across Europe, clinical laboratories, reference labs, and public health networks are major end users because they manage large sample volumes and require speed, consistency, and traceability.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Growing demand for genetic testing and personalized medicine
-
Technological advancements and automation
Level
-
High cost of advanced purification systems
Level
-
Expansion of point-of-care and rapid diagnostics
Level
-
Sample variability and technical hurdles
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing demand for genetic testing and personalized medicine
There has been a substantial rise in the demand for nucleic acid isolation and purification kits due to the focus on genetic screening and personalized medicine in the Europe market. As there is an emphasis on personalized medicine based on genetic information, the demand for extracting DNA and RNA in laboratories to perform these analyses has increased, thereby promoting the adoption of advanced nucleic acid purification kits and instruments.
Restraint: High cost of advanced purification systems
Advanced nucleic acid isolation instruments and kits mostly are high priced, which can limit adoption among smaller labs and academic institutions with limited budgets. The cost factor is a significant restraint, especially for advanced automated systems that provide high throughput and precision but require high capital investment.
Opportunity: Expansion of point-of-care and rapid diagnostics
There is an emerging need for more portable and rapid solutions for the isolation of nucleic acids that could be implemented at the point of care, in a clinic setting, or in a decentralized environment. Such rapid purification tools would enable more rapid decision-making for diagnosis, particularly with infectious diseases.
Challenge: Sample variability and technical hurdles
Different biological sample types (e.g., blood, tissues, saliva) present challenges due to diverse nucleic acid concentrations and inhibitory substances. Ensuring consistent recovery and purity across such varied matrices remains a technical challenge in the market, often requiring specialized protocols or reagents. Thus, sample variability is a practical challenge.
EUROPE NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
PHE Cambridge assessed an automated workflow using QIAsymphony RGQ along with artus CMV QS-RGQ assay for CMV DNA testing. | The workflow was positioned as highly suited for CMV DNA extraction and detection in urine and respiratory samples |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Europe nucleic acid isolation and purification market ecosystem comprises various constituents along the entire sample-to-result process. These include suppliers of extraction kits and reagents such as lysis buffers, silica columns, magnetic beads, and elution/wash chemistry. Apart from these participants, suppliers of automated instruments for extraction, which range from semi-automated to fully automated, user-friendly instruments for efficient extraction, can also be considered part of the Europe landscape. Additionally, Europe has participants in sample collection and stabilization tools like swabs, viral transport media, blood collection tubes for cfDNA, and RNA stabilization solutions.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Europe Nucleic Acid Isolation and Purification Market, by Product
In 2024, kits dominated the Europe nucleic acid isolation and purification market. This can be attributed to the consumables-intensive nature of nucleic acid extraction, which involves the use of DNA/RNA extraction kits in the process. Clinical and reference labs in the Europe market favor the use of kits due to their validity, standardization, and ease of operation by different operators.
Europe Nucleic Acid Isolation and Purification Market, by Type
In 2024, plasmid DNA isolation and purification dominated the Europe market. This is largely because plasmids are a core part of modern molecular biology workflows. European biopharma and biotech end users use plasmids heavily for gene and cell therapy development, viral vector programs, and mRNA/DNA platform work, where plasmid preparation is a requirement.
Europe Nucleic Acid Isolation and Purification Market, by Method
In 2024, magnetic bead-based isolation and purification accounted for the largest method segment in the Europe market. This is mainly because bead-based workflows are well-suited for automation and high-throughput processing, which many Europe clinical and reference labs rely on. The method delivers strong performance across a wide range of samples, including swabs, blood, plasma, and tissue lysates, while helping reduce inhibitor carryover in PCR- and NGS-linked testing.
Europe Nucleic Acid Isolation and Purification Market, by Application
In 2024, diagnostics was the dominant application in the Europe nucleic acid isolation and purification market. This is mainly because hospital labs, reference laboratories, and public health networks in Europe run large volumes of PCR and qPCR tests that depend on the extraction of clean DNA/RNA. Routine diagnostics in infectious diseases is still driving steady demand, and labs also need reliable extraction for respiratory panels, STI testing, sepsis workups, and blood-borne pathogen screening.
Europe Nucleic Acid Isolation and Purification Market, by End User
In 2024, hospitals and diagnostic centers dominated the Europe nucleic acid isolation and purification market by end user. This is mainly because they run the highest volume of routine PCR/qPCR diagnostics and increasingly support NGS-linked clinical testing. Large hospital networks and regional diagnostic hubs routinely process diverse sample types, so they need extraction workflows that are fast, standardized and repeatable across shifts and sites.
REGION
Germany to be the fastest-growing country in the Europe nucleic acid isolation and purification market during the forecast period
Germany is emerging as the fastest-growing country in the Europe nucleic acid isolation and purification market. This is supported by its strong diagnostics footprint and well-established life sciences ecosystem. The country has a dense network of hospital laboratories, reference labs, and research institutes, due to which it has a high demand for routine DNA/RNA extraction across the PCR and sequencing workflow.
EUROPE NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY EVALUATION MATRIX
In the Europe nucleic acid isolation and purification market matrix, Thermo Fisher Scientific (star) is a key player with strong reach across hospital labs, reference labs, academic institutes, and biopharma teams. Its portfolio covers magnetic bead- and column-based extraction kits, automation-ready workflows, and supporting plastics and buffers. LGC Biosearch Technologies (Emerging Leader) is enhancing its market position in Europe for enabling high-performance nucleic acid analysis.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific, Inc. (US)
- Danaher Corporation (US)
- QIAGEN (Germany)
- F. Hoffman-La Roche (Switzerland)
- Agilent Technologies, Inc. (US)
- Illumina, Inc. (US)
- Merck KGaA (Germany)
- Bio-Rad Laboratories Inc. (US)
- LGC Biosearch Technologies (UK)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 1.52 Billion |
| Market Forecast in 2030 (Value) | USD 2.41 Billion |
| Growth Rate | CAGR of 8.4% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Countries Covered | Germany, UK, France, Italy, Spain, and Rest of Europe |
WHAT IS IN IT FOR YOU: EUROPE NUCLEIC ACID ISOLATION AND PURIFICATION MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Europe diagnostics company planning to scale molecular testing |
|
|
RECENT DEVELOPMENTS
- September 2023 : QIAGEN launched two new nucleic acid extraction kits: the QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit, eco-friendlier versions of the RNeasy Plus Mini Kit and the All DNA/RNA Mini Kit.
- August 2023 : Danaher entered into a definitive agreement to acquire all the outstanding shares of Abcam. Through this development, Abcam is expected to operate as a standalone operating company within Danaher's Life Sciences segment.
- January 2023 : QIAGEN launched the EZ2 Connect MDx platform for automated sample processing in diagnostic labs.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Europe Nucleic Acid Isolation and Purification Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Europe Nucleic Acid Isolation and Purification Market